Expertise in
16
conditions

Dr. Chatchada Karanes

Internal Medicine
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 2 Trials
48 Years of Experience
Expertise in
16
conditions
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 

Overview

Chatchada Karanes is a primary care provider, practicing in Internal Medicine in Duarte, California. She has been practicing medicine for over 48 years.

Dr. Karanes is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Colonoscopy.

She is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 9 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

City of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Biological
Study Drugs: Unmanipulated Umbilical Cord Blood, AB-110
Study Phase: Phase 1
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2021
Intervention Type: Drug, Radiation, Procedure, Biological
Study Drugs: Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Thiotepa
Study Phase: Phase 2
View 7 Less Clinical Trials

35 Total Publications

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Journal: Blood
Published: June 07, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Geoffrey P. Shouse
Internal Medicine
Expertise in
30
conditions
Dr. Geoffrey P. Shouse
Internal Medicine

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Geoffrey Shouse is a primary care provider, practicing in Internal Medicine in Duarte, California. Dr. Shouse is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Follicular Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Expertise in
20
conditions
Dr. Raymond T. Chung
Internal Medicine
Expertise in
20
conditions
Dr. Raymond T. Chung
Internal Medicine

Orange County - Anaheim Medical Center

3440 E La Palma Avenue, 
Anaheim, CA 
 (20.5 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Chung is a primary care provider, practicing in Internal Medicine in Anaheim, California. Dr. Chung is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Cirrhosis, Liver Transplant, and Kidney Transplant. Dr. Chung is currently accepting new patients.

Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (23.7 miles away)
310-423-5161
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in West Hollywood, California. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Hyper IgE Syndrome, Splenectomy, and Bone Graft. Dr. Albert is currently accepting new patients.

Frequently Asked Questions about Dr. Chatchada Karanes

How do I make an appointment with Dr. Chatchada Karanes?

You can book an appointment with Dr. Chatchada Karanes by calling their office at 626-359-8111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chatchada Karanes a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chatchada Karanes is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chatchada Karanes specialize in?

While Dr. Chatchada Karanes is a Internal Medicine, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Chatchada Karanes participate in research or clinical trials?

Yes. Dr. Chatchada Karanes has published 35 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Chatchada Karanes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chatchada Karanes accept my insurance?

Dr. Chatchada Karanes accepts most major insurance plans, including UnitedHealthcare. We recommend calling the office directly at 626-359-8111 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karanes's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile